Key facts

Active Substance
Lacutamab
Therapeutic area
Oncology
Decision number
P/0483/2022
PIP number
EMEA-003281-PIP01-22
Pharmaceutical form(s)
Solution for injection/infusion
Condition(s) / indication(s)
Treatment of Cutaneous T-Cell Lymphoma
Route(s) of administration
Intravenous use
Contact for public enquiries

Innate Pharma SA

E-mail: info@innate-pharma.fr

Tel. +33 430303030

Decision type
W: decision granting a waiver in all age groups for all conditions or indications
Decision date

Decision

Share this page